The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis
Modern Rheumatology · 06.07.2024 · 34 (4) · 720-731
DOI: 10.1093/mr/road092 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, online erschienen am 14.09.2023. Verfasst von Yoshiya Tanaka und 13 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Evaluate the long-term safety and tolerability of anifrolumab 300 mg, alongside standard therapy, in patients from Japan with systemic lupus erythematosus (SLE) in the TULIP-LTE trial (NCT02794285).
Methods
TULIP-LTE was a 3-year, randomized, double-blind, placebo-controlled long-term extension (LTE) of the TULIP trials. The primary safety outcome included serious adverse events (SAEs) and AEs of special interest (AESIs) during the LTE period. Exploratory efficacy outcomes included SLE Disease Activity Index 2000 (SLEDAI-2 K) scores and glucocorticoid use. We performed a post hoc subgroup analysis of patients who enrolled in Japan.
Results
Exposure-adjusted incidence rates of SAEs during the LTE and follow-up for patients receiving anifrolumab 300 mg (n = 21) were 8.7 per 100 patient-years; AESIs included influenza (6.9) and herpes zoster (3.5). One of three patients receiving placebo had an SAE (13.9). One patient per group discontinued due to an AE. There were no deaths. During the TULIP + LTE period, patients receiving anifrolumab 300 mg (n = 24) had sustained reduction from baseline in mean SLEDAI-2 K scores and cumulative glucocorticoid dosage.
Conclusions
Anifrolumab 300 mg showed a favourable benefit-risk profile for the long-term treatment of adult patients with moderate to severe SLE from Japan, with safety, tolerability, and efficacy profiles consistent with the overall population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
- Department of Rheumatology, Endocrinology, and Nephrology, Hokkaido University, Sapporo, Japan.
- Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan.
- Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
- Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan.
- Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan.
ORCID-Profile: Yoshiya Tanaka
Zitieren
APA
Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., Matsumura, R., Kawakami, A., Hayashi, N., Abreu, G., Yavuz, S., Lindholm, C., Al-Mossawi, H., & Takeuchi, T. (2024). The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis. Modern Rheumatology, 34(4), 720-731. https://doi.org/10.1093/mr/road092
Vancouver
Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, et al. The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis. Modern Rheumatology. 2024;34(4):720-731. doi:10.1093/mr/road092
BibTeX
@article{Tanaka2024,
author = {Tanaka, Yoshiya and Atsumi, Tatsuya and Okada, Masato and Miyamura, Tomoya and Ishii, Tomonori and Nishiyama, Susumu and Matsumura, Ryutaro and Kawakami, Atsushi and Hayashi, Nobuya and Abreu, Gabriel and Yavuz, Sule and Lindholm, Catharina and Al-Mossawi, Hussein and Takeuchi, Tsutomu},
title = {The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis},
journal = {Modern Rheumatology},
year = {2024},
volume = {34},
number = {4},
pages = {720--731},
doi = {10.1093/mr/road092}
}
EUVIMED